reason report
stand alon sea neoantigen vaccin initi op
bottom line initi coverag genocea gnca
outperform rate price target posit view base
promis genocea atlastm immuno-profil platform
applic empir identif neoantigen vaccin
cell therapi clinical-stag neoantigen vaccin compani use
empir select neoantigen genocea exposur risk
come relianc silico predict platform furthermor
atlastm alon abil identifi inhibitori neoantigen
may immuno-suppress effect negat benefit
stimulatori t-cell respons moder excit like
difficulti interpret clinic signal on-going combin
trial capit requir fund develop clear signal
concentr pipelin risk well choic peptid
vaccin modal nonetheless ev believ gnca
opportun under-appreci minim downsid
confid atlastm increas sinc
biolog valid came genocea broader industri
believ data overlook investorsmarket
reaction reflect de-risk stori
antigen identifi atlastm fact immuno-
benefit stimulatori neoantigen drove tumor progress
one medacorp kol react new data sum
well pretti clear scienc inhibitori antigen longer
say bacteria vitro system expect genocea continu
work understand biolog mechan inhibitori
neoantigen provid valid platform
averag stimulatori neoantigen per patient
atlastm hit rate surprisingli high pioneer neoantigen
work nation cancer institut nci research typic found
two neoantigen specif tumor-infiltr lymphocyt til
per patient though genocea confirm atlastm antigen
vitro stimul iv elispot assay heard caution
medacorp kol genocea neoantigen may produc weak t-
cell respons vivo and/or larg promiscu septemb
year research peng et al cell report use
complet differ empir method neoantigen identif similarli
found averag neoantigen per patient assay hla
restrict nci also publish small head-to-head
case report show new til select process increas
number neo-antigen til identifi yossef et al
insight genocea larger set neoantigen prove elicit
potent anti-tumor cell respons could huge advantag
blend dcf multipl analysi
use wacc account
net cash project revenu
rang outcom
mont carlo simul entir io
net debt total capit
year price history/av daili volume mil gnca
compani inform svb leerink llc research
ep quarterli figur may sum annual total due chang share outstand
pleas refer page import disclosur price chart analyst certif
also societi immunotherapi cancer nov
genocea share vitro data show neoantigen identifi
atlastm miss open-sourc predict algorithm
elicit t-cell respons patient confirm
atlastm correctli identifi neoantigen miss predict
clinic proof-of-concept genocea lead program
could come studi design could make data
interpret challeng genocea current recruit metastat
patient phase trial combin
base standard-of-car enrol patient io-respons
tumor could multipl background agent make
difficult discern vaccin signal genocea plan use patient
control compar improv respons period
vaccin background therapi also
confound analysi sinc deepen respons observ
checkpoint therapi multipl tumor type
collabor like prove vital genocea see clear
biolog rational underpin gnca approach translat
vivo efficaci ultim posit optim strategi neoantigen
identif could incorpor element empir identif
silico base method believ genocea could uniqu situat
broadli licens tech player field exampl
compani research collabor iovanc cover could
evolv licens arrang
stand alon sea neoantigen vaccin
initi genocea gnca outperform price target
estimate
eq
genocea gnca micro-cap biotech
develop neoantigen-target therapi
gnca distinguish among neoantigen vaccin
competitor one use empir
silico select clinic
stage compani select avoid inhibitori
lead program neoantigen vaccin
on-going studi select solid tumor
interim readout expect
neoantigen target cell therapi set
enter clinic next year
asset genit herp
compani look partner
ind file adopt t-cell
efficaci data part studi
vaccin
invest thesi empir atlastm immuno-profil platform potenti accur
approach identifi neoantigen vaccin cell therapi
atlastm alon abil identifi inhibitori neoantigen may immuno-suppress effect
negat benefit stimulatori t-cell respons
clinical-stag neoantigen vaccin compani use empir select neoantigen genocea
exposur risk come relianc silico predict platform
genocea could uniqu situat broadli licens tech vaccin cell therapi player
ev believ genocea opportun under-appreci
project revenu gener rang outcom deriv mont carlo
simul entir io industri pipelin valuat price target base blend dcf
multipl analysi use wacc account net cash current share price see
limit downsid risk gnca
interpret clinic signal on-going combin trial like difficult may muddi
genocea capital-constrain would like need partner fulli realiz valu platform
peptid may may prove effect modal cancer vaccin
scale person manufactur process may requir time cost anticip
program
valu cash nol
nol overhead
nol overhead
use
part data
difficult interpret given
single-arm combin
of-car numer small
pipelin
asset valu remain
program earli
assum launch
close
develop ultim
uptak
adjuv approv
de-risk valu
addit shot goal
indic like
benefit vaccin
earli focus pipelin lean correl risk
depict gnca readi genit herp vaccin compani look partner strateg reason partnership materi two
year sinc program depriorit revenu realiz program would upsid view
dcf/multipl blend part sotp valuat
neon struggl sinc releas clinic data
genocea attract valu public neoantigen vaccin compani
base biontech current
ev estim make
biontech valu
up-front
base ev
estim make
valu
contribut mrna total revenu consensu note applic
learn past
vaccin til tcr-t cell therapi aim kick-start immun
respons tumor specif antigen
present
prime
chen mellman immun
vaccin tcr-
cell activ
lab
cancer vaccin rare demonstr efficaci despit hundr
clinic studi variou approach differ clinic set
cancer vaccin trial start year antigen modal
academic/ longer activ program
dc autolog vaccin
despit volum studi proveng remain cancer vaccin gain fda approv
scientist hope improv gener vaccin final enabl clinic success
multipl antigen neoantigen combin checkpoint inhibitor
cancer vaccin success requir start optim design overcom histor challeng
failur provid mhc
 mhc ii respons
hla restrict breadth
neoantigen vaccin may
multipl modal parallel hedg
subcutan inject mount
immun respons skin fail
provid t-cell home direct
tumor melanoma
vaccin gener respons
slow address bulki fast-
share antigen often pre-
immune-edit provid rout
particularli epitop
dispens tumor surviv
competitor novel platform
dendrit cell
checkpoint provid rapid respons
prevent exhaust vaccin stimul
well-known adjuv avail stimul
dc prevent toler prime
wealth io asset may synergist
use multipl antigen prevent tumor escap
neo-epitop uniqu share less pre-
exist toler may oncogen
believ mrna sever advantag modal medacorp
kol agnost
short half-lif
best
often reli
process long
class ii peptid
may self-amplifi
readili taken
use whole protein
signal class ii
engin deliveri
need cross
nuclear membran
pre-exist immun
safeti risk
viru bacteria
requir prime boost
qualiti requir
risk genom
seem get antigen-specif t-cell modal
pragmat go easiest quickest cheapest produc medacorp kol
sourc guo et al santo butterfield medacorp vaccin kol
potenti combin strategi neoantigen vaccin
cytokin
may lead greater potent cell
sting tlr
tumor may lead releas
chemokin direct new
cell tumor
sting
apc matur antigen
chemotherapi radiat tki may reduc tumor
burden slow progress immun respons build
chen mellman immun
checkpoint anti-
immun suppress
extend durabl effect
data multipl trial expect near-term posit
read-through entir neoantigen vaccin class
immun data
esmo-io dec
immun data
esmo-io dec
challeng
though sever neoantigen vaccin clinic major question remain unansw
neoantigen predict algorithm
unknown lack experiment valid
neoantigen specif t-cell see elispot
assay effect clear tumor
certainli improv time human data
ad train set
vaccin enough
unknown expect neo-epitop rate debat
neoantigen prevent tumor immune-
number neoantigen predict hit rate valid
unclear whether enough patient sampl
collect act neoantigen clonal
determin best way
cautious posit peptide-bas mrna
administ deliv neoantigen
vaccin shown evid induc
neoantigen specif immun clinic respons
select right patient
enough tumor mutat burden tmb
neo-epitop also unmet
need neoantigen specif cell
unknown patient high tmb like
neo-epitop leav room error
predict know whether
patient may benefit least addit cell
til success melanoma suggest high-tmb
patient benefit addit stimul
neoantigen play central role cancer immun cycl disrupt
one step enabl tumor immun evas
neoantigen releas die cancer cell
captur antigen present cell apc
recognit lead
tumor cell kill
apc prime cell
tumor lymph node
infiltr tumor bed
adapt yi et al note neoantigen mutat peptid neo-epitop neoantigen peptid bound mhc apc
neoantigen sever advantag antigen
challeng must address
type tumor
advantag
share mani
typic
express
restrict
cell test
central
immunogen
rare express
effect
 challeng
restrict
autoimmun
due central
elimin
due broad
elimin
due self-
express
portion
frequenc
abil escap
tran robbin rosenberg ure immunolog problem neoantigen predict biotechnol
driver
suscept immuno-
edit like
share
least whole exom
sequenc we
neoantigen
immunogen
may clonal
correl case studi data establish neoantigen drive
effect tumor specif cell respons human
neoantigen burden associ
greater likelihood durabl
clinic benefit dcb vs durabl
benefit ndb improv
investig found greater
baseline-abund neoantigen
specif cell respond
well enrich neoantigen
specif cell
numer case studi complet
durabl respons til enrich
neoantigen reactiv cell
nsclc patient treat atezolizumab
numer strategi prime immun respons neoantigen could
theoret kick-start durabl tumor-immun respons
respons
isol expand
tumor
vivo neoantigen-
peptid dc
tumor suffici
pre-exist de
clinic valid
pre-exist de novo
pre-exist de novo
nci iovanc
improv efficaci
vaccin
lower bar
product time
optim
deliveri dc
labori costli
tumor type
stimul ex vivo
set without need
optim vivo deliveri
dc stimul
improv efficaci
labori costli
thu far limit
smaller number
challeng expand
cell simultan
peptid vari
respons
engin
clinic valid
car-t tcr
labori costli
use
bar significantli
compani activ vivo neoantigen vaccin program
neoantigen-load mrna complex
neoantigen-load mrna complex
viral prime self-amplifi rna boost
granit share slate
screen stimulatori inhibitori
prime-boost vaccin neo-
five
neoantigen-load mrna complex
lipid nanoparticl proprietari carrier
dna cassett format plasmid
design induc strong cell
neoantigen specif tcr til
screen stimulatori inhibitori
select rare neoantigen tcr
replac endogen tcr
non-vir dna donor
hla-peptidom identifi neo-
epitop present tumor
replac endogen tcr cell
identifi neoantigen reactiv
non-vir sleep beauti transposon
potenti overnight cell engin
could time advantag
isol expans enrich
patient til re-infus
preclin collabor gnca
peleustm platform select
svb leerink compani websit riba esmo present cancer genom neoantigen
result iova til valid neoantigen target
earli data present trial iova autolog til therapi isol
patient biopsi sampl expand re-infus show respons rate meet
lifileucel show object respons rate orr independ review
committe irc metastatic/unresect melanoma patient previous progress
median durat respons dor reach median
show orr previous treat cervic cancer median dor
reach median line nivolumab ipilimumab
set orr cr median dor reach
naumann esmo result checkmat
single-ag combin clinic respons neoantigen
vaccin report nsclc melanoma
peptid vaccin object
respons rate includ one cr
respons patient egfr
mutat narrow sub-
object respons two five
patient measur metastat lesion
increas neoantigen specif cell follow
vaccin one respond influenza intern control
collabor tianjin beichen hospit md anderson cancer center bostongen
identifi neoantigen compani scientist focus one
step process mutant gene stimul cell
tcr recogn neo-epitop exist
dendrit cell prime activ cell
high
peptid
transport
membran
mutant protein
degrad
transport er
peptid bind
mhc-i er
adapt yi et al er endoplasm reticulum transport associ antigen process
sever compet approach identifi neoantigen
genocea uniqu among vaccin compani use empir select
predict peptid
could fit groov
base machin learn
train set vitro
present tumor mass
employ assay empir
select cell tcr
bind stimul
therapeut set
requir whole-exom
direct identif class
ii neo-epitop well
antigen taa
ignor tcr presenc
neo-epitop express
depend qualiti
size train set
drawback
ignor tcr presenc
poor sensit
contain hydrophob
difficult predict hla-
publish new approach
distinguish surfac
er present
alreadi present databas
identifi
approach
ignor neo-epitop
select threshold til
pre-select
incorrect feedback loop
optim long
screen til select
pre-exist immun
sourc gfeller bassani-sternberg front immunol bassani-sternberg et al natur karaora et al oncotarget yossef et al insight
riba esmo present cancer genom neoantigen genocea esmo bulik-sullivan et al natur biotechnolog abelin et al immun
found difficult assess valid compani claim
claim proprietari algorithm dont believ rearrang deck
chair algorithm there way know whether true wash
unless data convinc someon someth differ medacorp kol
high-throughput empir identif method fulli
character advantag drawback
compar
empir
use patient dc pool
potenti neoantigen
reactiv til subset
til pre-select base
use coli express
system dc deriv
patient monocyt patient
 cell identifi
immuno-stimulatori
multi-step synthet
biolog process identifi
neoantigen specif cell
patient tumor peripher
select til elicit clinic
neoantigen addit
cost effect
high sensitivitysometim
select approach
threshold activ
til immunogen
may high
pool approach swamp
signal singl
cell potenti de
novo respons could
peripheri tumor
risk bacteria presenc
claim
coverag hla
silico predict
algorithm first filter
may increas risk
though pioneer nci work suggest product neo-epitop
neoantigen til show
neoantigen
recogn neo-epitop til
almost til-recogn neo-epitop
share across patient
typic found per patient
none
three
studi patient respond
show
tumor neoantigen associ til
latest iter empir neoantigen screen includ genocea
atlastm find neoantigen
genocea neoantigen number feel
believ actual number neo-epitop
higher initi til work suggest
process select may gate
effect cell see dc use
screen may effect present
peptid threshold function assay
may high
high compar tor nci
line recent publish case
pact pharma note hla-restrict
publish screen would
captur subset neoantigen
nci report mutat mutat screen assum nonsynonym mutat
patient cohort screen nci tandem minigen method
exclud one outlier stimulatori neoantigen includ outlier give averag
nci til select neoantigen screen
red outlin show gate flow cytometri
empir screen suggest silico predict especi reli
antigen-mhc bind affin may miss numer neo-epitop
peng et al found mrna express level left
much stronger correl strength
neoantigen antigen-mhc bind affin
genocea poster addit patient exampl note perspect genocea test fluorospot result predict epitop
found atla
nation cancer institut leverag neoantigen express patient
dc identifi reactiv neoantigen cell patient tumor
select like antigen-activ tumor-
infiltr lymphocyt til base
multipl neoantigen peptid tandem mini-
gene patient dendrit cell dc screen
deconvolut signal specif neoantigen repeat
entir process test neoantigen peptid
genocea atlastm platform leverag bacteri express
potenti neoantigen identifi patient specif neoantigen
cllo
movement
cytosol load
mhc-i
without cllo neoantigen
load mhc-ii
potenti neoantigen coli use
patient monocyte-deriv dendrit cell present
potenti neoantigen patient cell
detect immuno-stimulatori immuno-
inhibitori neoantigen compar
cytokin background secret
pact pharma combin predict algorithm multi-step synthet
biolog process identifi neoantigen specif cell
pnp potenti neo-epitop snare cell
patient sampl blood tumor use high avid copi
tetram
note focus neoantigen identif portion pact pharma process see sourc use produc neoantigen specif tcr cell therapi
snare cell isol use magnet pull-down
decod single-cel microfluid trap base uniqu dna
code pnp
identifi inhibitori neoantigen uniqu capabl atla
genocea believ use vaccin design biomark
interrog cytokin releas respons antigen compar baselin
bacteria control atlastm genocea identifi stimulatori inhibitori neoantigen
gnca defin stimulatori inhibitori respons induc cytokin secret median absolut
deviat baselin control mean
genocea stand alon make case inhibitori neoantigen believ
recent murin data present refut critic argument
doubt rais us competitor inhibitori neoantigen artifact bacteria gnca assay
evid genocea refut
murin vaccin
inhibitori neoantigen result
doubt rais us medacorp kol inhibitori neoantigen inconsequentialbreak regulatori
respons neoantigen may power
evid genocea refut
mice inhibitori
compet suppress
respons stimulatori
read vitro elispot
note assay use previous publish stimulatori neoantigen ag
comparison clinic
result neoantigen
without larg single-arm random clinic data set compar
vaccin platform use sever biomark pragmat consider
criteria comparison
potent vaccin detect lower sensit assay cell respons
given proport neoantigen specif cell effect kill
tumor neo-epitop may express tumor
subclon higher raw number immunogen neoantigen posit signal
higher percent immunogen neoantigen signal better select platform
believ well-establish helper cell
neoantigen respons necessari durabl tumor control
effect neoantigen vaccin elicit respons
show tumor infiltr cell anoth posit signal
single-ag respons random data gold-standard
combin look ppt absolut orr increas
patient hit proof-of-concept
chang rate tumor shrinkag metastasi interest earli signal
time cost
product cost low enough support econom repeat treatment
possibl combin io therapi
person vaccin need manufactur quickli possibl address
inspir riba propos slide svb leerink
though mdacc single-ag clinic respons
genocea immunogen data stand among competitor
compani posit data
magnitud immun respons
particularli best-in-class
though avail absolut count
though method differ small could
explain variat stand percent
neoantigen per patient respons iv
impress
neoantigen select data
respect neoantigen gener
ex vivo respons
genocea present first clinic data
mdacc shown single-ag
clinic respons vaccin
time cost
longer turn-around time
peer risk genocea scale
hope improv
note vaccibodi also report data neoantigen vaccin combin yet incorpor analysi
detect ex vivo t-cell respons signal strong vaccin immunogen
magnitud immun respons particularli best class
pbmc overnight exposur
peptid ifn elispot
pbmc expos one day
pbmc expos rna-load
cell deplet pbmc expos
peptid ifn
median per
cell wk
cell
cell
cell day
ifn grb
result publish detail italic confirm variabl test conduct time make direct comparison challeng
though method differ small could explain variat
gnca stand percent neoantigen gener respons
antigen vaccin
subcutan
subcutan
dose
dose
intranod
average neoantigen
gener cell respons
iv
iv
iv
subcutan
dose
iv
average neoantigen
iv
iv
iv
major ex
iv
average neoantigen
iv
iv
iv
cell respons elispot/
iv
patient t-cell
neoantigen tmb yield
patient receiv
evid tumor infiltr
patient dcb
stim
estim neovax predecessor respect use differ neoantigen select process otherwis ident
on-going intraven deliv rna-lpx formul benefit dc target may underst potenti dcb durabl
longer turn-around time peer risk
genocea scale hope improv
person therapi time manufactur critic delay lead progress patient
withdraw less attract therapi commerci set
manufactur time longer peer use silico and/or mrna potenti
ad time atlastm screen
though believ improv time approach reduc impact slower turn-around
time includ move adjuv set and/or use combin sequenc combin partner first
neither approach relev early-phas single-arm signal find
popul
receiv
time recent
prospectu
week
clinic immun respons data catalyst neoantigen vaccin
program could help valid field whole
open-label tecentriq
random keytruda
part adjuv set poly-iclc
adjuv part metastat set
poly-iclc adjuv
open-label opdivo yervoy
open-label opdivo yervoy
preliminari data
part
safeti data
esmo-io dec
clinic data mid-
open-label alon adjuv
keytruda r/r solid tumor
random keytruda high-
risk melanoma complet resect
single-arm opdivo poly-
single-arm keytruda chemo
poly-iclc adjuv
non-random poly-iclc
adjuv opdivo either yervoy
data
random checkpoint inhibitor
trial start
clinic data
part genocea phase trial provid immunogen signal proof-
of-platform principl clinic signal meaning given set size
phase part portion administ single-ag small cohort patient
updat result present eight patient treat part show
patient remain recurr free median mo first dose
patient immun respons detect ex vivo
enrol patient receiv treatment three insuffici stimulatori
antigen tumor avail one progress prior vaccin
bladder cancer melanoma nsclc rcc part scchn da diseas assess adapt cohen et al
part interest trial may difficult teas posit signal
believ risk genocea asco get interim data
anticip multipl challeng interpret part metastat cohort data
cohort part tumor type respons immuno-therapi increas background
threshold must exceed give posit signal
genocea allow standard-of-car io background pembrolizumab chemo single-ag
nivolumab ipilimumab reduc number patient one hypothesi test
potenti clearest signal may come cohort patient progress io treatment
readi patient receiv io-refractori set much
orr part studi fail meet promis expect would expect gnca stock
fall cash downsid scenario reflect recent experi neon although note current
level gnca stock alreadi heavili discount
minimum desir rr expect part interim histor refer
ci platinum inelig
rcc
scchn
 larkin et al nejm top-lin
pembrolizumab data taken label svb leerink
neon experi give us good sens high investor expect
poor recept phase data neon reflect challeng interpret combin data
absenc control arm respons rate gener fail meet benchmark promis
signal neon stock sinc first report clinic data esmo
expect investor also compar genocea result directli neon phase given similar
program peptid vaccin poli iclc adjuv patient treatment
data studi neoantigen vaccin
promis data nsclc
patient receiv vaccin pembrolizumab combin pr patient progress cpi orr includ patient
develop cr single-ag keytruda run-in prior vaccin note applic
provid neon clinicaltri gov
financi
chief
presid chief execut offic sinc februari previous chief busi offic august
februari mr clark also serv board director sinc februari prior genocea serv
chief busi offic co-found prior vanda mr clark princip
capit ventur capit firm invest biopharmaceut compani serv varieti commerci
strateg role smithklin beecham glaxosmithklin hold harvard univers
 wharton school univers pennsylvania
chief medic offic sinc oct previous serv chief medic offic gadeta dutch cell therapi
compani pursu novel cancer target prior dr davi serv chief medic offic celldex
also previous serv chief medic offic genvec senior director clinic scienc
medarex prior join industri dr davi supervis clinic effort cancer therapi evalu program
ctep nation cancer institut nci work develop rituximab idiotyp vaccin
stanford univers dr davi receiv biophys john hopkin physiolog
georgetown univers complet fellowship medic oncolog stanford univers
dr flechtner join genocea soon compani found current serv chief scientif offic
prior join genocea serv varieti role develop vaccin immunotherapi cancer infecti
diseas autoimmun allergi compani includ mojav therapeut antigen dr
flechtner receiv anim scienc ph cellular immunolog cornel univers perform
post-doctor work dana farber cancer institut harvard medic school
ms duval join genocea march previous vice presid control chief account offic
bioverativ inc prior serv global commerci control held number
posit execut director merck co ms duval receiv bachelor degre econom public
polici colbi colleg master degre account busi administr
univers also certifi public account licens state massachusett
dr aakalu join genocea decemb chief busi offic prior role includ serv vice presid
global head extern innov ipsen group execut director head strategi innov oper
pfizer extern innov team previou role also includ busi develop oncolog pipelin
market plan posit genentech inc life scienc consult experi consult receiv
 biophys gener department honor john hopkin univers ph cellular
molecular neurobiolog follow biolog california institut technolog complet
execut educ corpor govern northwestern univers kellogg school manag
scientif advisori board stack physician scientist
expertis vaccin oncolog
intern recogn vaccin expert decad experi develop innov vaccin dr siber
prior profession experi includ execut vice presid chief scientif offic wyeth vaccin
research overse develop approv market six innov childhood vaccin previou
wyeth dr siber serv associ professor medicin harvard medic school director
massachusett biolog laboratori current dr siber chief scientif offic clearpath vaccin compani
vaccin develop compani focus develop novel vaccin high medic need creat global
vaccin portfolio astella pharma dr siber receiv undergradu degre bishop univers lennoxvil
quebec medic degre mcgill univers montreal
influenti leader immunotherapi prostat cancer research therapi previous dr drake serv
co-director cancer immunolog program john hopkin school medicin co-director
prostat cancer multi-disciplinari clinic dr drake receiv electr engin biomed
engin rutger univers receiv doctor nation jewish center immunolog
respiratori medicin univers colorado health scienc center later earn medic degre
univers colorado
expert target mutat neoantigen use adopt cell transfer act therapi studi provid
direct evid cell target neoantigen mediat tumor regress patient metastat
epitheli cancer dr tran earn ph univers victoria british columbia canada receiv
postdoctor train nation cancer institut nation institut direct mentorship dr
steven rosenberg leader pioneer human cancer immunotherapi
leader preclin earli clinic develop vaccin breast pancreat cancer john hopkin
dr jaffe deputi director sidney kimmel comprehens cancer center associ director
bloomberg-kimmel institut cancer immunotherapi co-director skip viragh center pancrea
cancer clinic research patient graduat magna cum laud brandei univers
receiv medic degre new york medic colleg
leader develop mous model lung cancer dr wong made contribut understand
origin cancer molecular determin treatment respons follow distinguish career
harvard medic school dana-farb cancer institut dr wong current professor medicin
practic clinic oncologist nyu langon health center dr wong earn ph integr
program cellular molecular biophys studi columbia univers colleg physician surgeon
train intern medicin massachusett gener hospit hematology-oncolog dana-farb
object interpret result single-arm combin trial oncolog
inspir riba propos
threshold requir posit early-stag signal
set
ppt orr patient
promis result larger size need verifi
set
activ
set
ppt orr less patient
ppt delta orr patient
ppt delta orr less patient
ppt delta orr patient
ppt delta orr
proof concept poc fabul signal move aggress registration-en trial
promis intrigu signal confirm signal increas patient number and/or random phase data
poor signal littl evid efficaci project discontinu
also depriorit unaccept toxic pazopanib rcc random os need demonstr combin synergist synergist
sequenc may prefer given toxic expens antoni riba note sourc may requir subscript
neoantigen target role outsid melanoma
mutagen tumor melanoma serv proof-of-concept indic neoantigen
vaccin much like checkpoint inhibitor patient tumor type enough
neo-epitop benefit vaccin
melanoma also benefit t-cell natur tendenc home skin kol spoken agre
cell home tumor may challeng outsid melanoma
ph schema efficaci assess
year note current
criteria allow
chemotherapi
patient
interpret could
confound deepen
respons observ
checkpoint therapi
atla platform protect three patent famili includ five issu us patent compani
licens exclus world-wide right platform harvard univers remain elig minim
amount mileston low single-digit royalti commerci product aris
model loss exclus year estim first approv
method relat atla discoveri
discoveri cancer tumor relat
antigen atla
method cancer diagnosi
prognosi patient select
well relat composit addit
famili relat select cancer
tumor relat antigen
region
europ canada
europ canada
